Compare AstraZeneca plc (AZN) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Macy's Inc — how do they compare? AstraZeneca plc trades at $166.5 (market cap $253.13B), while Macy's Inc trades at $23.12 (market cap $6.11B). The key difference: AstraZeneca plc is far larger — about 41.4× Macy's Inc's market cap, and Macy's Inc pays the higher dividend (3.3%). Which is the better fit depends on your goals.
| AZN | M | |
|---|---|---|
Market Cap | $253.13B | $6.11B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $25.96 |
52-Week Low | $137.44 | $11.90 |
Enterprise Value | $279.37B | $9.92B |
Dividend Yield | 1.92% | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Macy's (M) trades at $22.78, up 0.62% on the day, with a neutral technical signal. The stock shows attractive valuation metrics, including a P/E of 9.41 and P/S of 0.28, alongside improving cash flow and a recent earnings beat streak. The 'Bold New Chapter' strategy is driving operational improvements, with Berkshire Hathaway's new stake in Q1 2026 signaling institutional confidence.
The outlook is cautiously optimistic, supported by low valuation and strategic initiatives, but risks include margin pressure from retail sector headwinds and execution challenges in the turnaround plan. Analyst consensus is mixed, with a $24.83 price target suggesting modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
